Last reviewed · How we verify

NCT06627725

The Effect of Patient-Family Communication Via Audio Recording

Completed NA Last updated 4 October 2024
What this trial tests

NA trial testing Patient-Family Communication in Anxiety in 55 participants. Completed in 10 June 2023.

Timeline
10 May 2022
Primary endpoint
10 June 2023
10 June 2023

Quick facts

Lead sponsorYasemin Kalkan Uğurlu
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment55
Start date10 May 2022
Primary completion10 June 2023
Estimated completion10 June 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Yasemin Kalkan Uğurlu

Who can join

18 and older, any sex, with Anxiety or Anxiety Depression (Mild or Not Persistent). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study was conducted as a randomized controlled blinded study. The sample consisted of 55 patient relatives (27 in the experimental group and 28 in the control group). The patient's relatives in the experimental group said what they wanted to say to their patient in line with the content determined by the researchers and recorded it using a voice recorder. The researcher played the recorded message to the patient, and the patient's feedback was conveyed to the patient's relative.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anxiety

Currently open trials in the same condition.

Other Yasemin Kalkan Uğurlu trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06627725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing